28 / 164
158
for reducing the risk of atherosclerotic disease. Eur Heart J
2007;28:5-12.
12. Mooradian AD, Haas MJ, Wong NC. Transcriptional control
of apolipoprotein A-I gene expression in diabetes. Diabetes
2004;53:513-520.
13. Beers A, Haas MJ,Wong NC, Mooradian AD. Inhibition of
apolipoprotein AI gene expression by tumor necrosis factor
alpha: roles for MEK/ERK and JNK signaling. Biochemistry
2006;45:2408-2413.
14. Vergès B, Petit JM, Duvillard L, et al. Adiponectin is an important
determinant of apoA-I catabolism. Arterioscler Thromb Vasc
Biol 2006;26:1364-1369.
15. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary
artery disease in non-insulin dependent diabetes mellitus:
United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ
1998;316:823-8.
16. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin
North Am 2004;88:897-909.
17. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the
American Collegue of Cardiology/American Heart Association
Task Force on Practice Guidelines. Circulation 2014; 129
(Suppl 2):S1-S45.
18. American Diabetes Association. Cardiovascular disease and risk
management. Diabetes Care 2015; 38 (Suppl): S49-S57.
19. Catapano AL, Reiner Z, De Backer G, et al ESC/EAS Guidelines
for the management of dyslipidaemias: the Task Force for
the management of dyslipidaemias of the European Society
of Cardiology (ESC) and the European Atherosclerosis Society
(EAS).Task Force for the management of dyslipidaemias of
the European Society of Cardiology (ESC) and the European
Atherosclerosis Society (EAS), ESC Committee for Practice
Guidelines 2008-2010 and 2010-2012 Committees.
Atherosclerosis 2011 Jul;217 (Suppl 1):S1-44.
20. Grundy SM. An International Atherosclerosis Society Position
Paper: global recommendations for the management of
dyslipidemia. J Clin Lipidol 2013; 7: 561-565.
21. h t t p : / / www . r e d c r o n i c a s . c l / t ema s - d e - s a l u d / s a l u d -
cardiovascular-2/enfermedades-cardiovasculares/
22. Jacobson T, Ito MK, Maki KC, et al. National Lipid Association
recommendations for patient-centered management of
dyslipidemia: part 1 - executive summary. J Clin Lipidol 2014.
8: 473-488.
23. Dattilo
AM,
Kris-Etherton
PM.
Effects
of
weight
reduction on blood lipids and lipoproteins: a meta-
analysis. Am J Clin Nutr 1992; 56: 320-328.
24. Wing RR, Lang W, Wadden TA et al. Benefits of modest weight
loss in improving cardiovascular risk factors in overweight and
obese individuals with type 2 diabetes. Diabetes Care 2011;
34:1481-1486.
25. Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of
cardiovascular disease with a Mediterranean diet: N Eng J Med
2013; 368:1279-1290.
26. Kearney PM, Blackwell L, Collins R, et al . Cholesterol Treatment
Trialists’ Collaborators. Efficacy of colesterol lowering therapy
in 18686 people with diabetes in 14 randomized trials of
statins: a meta-analysis. Lancet 2008;371:117-125.
27. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident
diabetes: a collaborative meta-analysis of randomised statin
trials. Lancet 2010;375:735-742.
28. Preiss D, Sattar N. Statins and the risk of new-onset diabetes:
a review of recent evidence. Curr Opin Lipidol 2011;22:460-
466.
29. Baker WL, Talati R, White CM, Coleman CI. Differing effect of
statins on insulin sensitivity in non-diabetics: a systematic
review and meta-analysis. Diabetes Res Clin Pract 2010;
87:98-107.
30. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by
simvastatin, but not pravastatin, of glucose-induced cytosolic
Ca2+ signalling and insulin secretion due to blockade of L-type
Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;
126:1205-1213.
31. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for
cholesterol lowering in 2,722 people: systematic review and
meta-analysis of randomized controlled trials. J Intern Med
2009; 265: 568-580.
32. Ballantyne CM, Weiss R, Moccetti T, et al. EXPLORER Study
Investigators. Efficacy and safety of rosuvastatin 40 mg alone
or in combination with ezetimibe in patients at high risk of
cardiovascular disease. Am J Cardiol 2007;99:673-680.
33. Nakamura T, Hirano M, Kitta Y, et al. A comparison of the efficacy
of combined ezetimibe and statin therapy with doubling
of statin dose in patients with remnant lipoproteinemia on
previous statin therapy. J Cardiol 2012; 60: 12-17.
34. Christopher P. Cannon, M.D., Michael A, e al. IMPROVE-IT
Investigators. Ezetimibe Added to Statin Therapy after Acute
Coronary Syndromes. N Engl J Med 2015; 372:2387-2397.
35. Filippatos TD, Elisaf MS. Statin-Ezetimibe Combination
Therapy In Diabetic Individuals. Angiology. 2015 pii:
0003319715598887. (Epub ahead of print).
36. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of
action and therapeutic applications for agonists of peroxisome
proliferator-activated receptors. Nat Clin Pract Endocrinol
Metab 2007;3:145-156.
37. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group.
Effects of combination lipid therapy in type 2 diabetes mellitus.
N Engl J Med, 2010 362:1563-1574.
38. Davidson MH, Armani A, McKenney JM, Jacobson TA.
Safety considerations with fibrate therapy. Am J Cardiol
2007;99:3-18.
39. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety,
and tolerability of once-daily niacin for the treatment of
dyslipidemia associated with type 2 diabetes: results of the
assessment of diabetes control and evaluation of the efficacy
of Niaspan trial. Arch Intern Med 2002; 162:1568-1576.
40. Poynten AM, Gan SK, Kriketos AD, et al. Nicotinic acid- induced
[REV. MED. CLIN. CONDES - 2016; 27(2) 152-159]